AXL and neoplasm: Consistent with in vitro experimental results, cotreatment with bevacizumab and ramucirumab drastically diminished tumor angiogenesis, as evidenced by decreased CD31‐positive staining (Figure 7F), and suppressed the expression of angiogenesis and drug resistance‐related genes, FGF and YAP/TAZ/AXL (Figure 7G).